Phase II Study for Combination of Camrelizumab and Apatinib in the Second-line Treatment of Recurrent or Metastatic Adrenocortical Carcinoma

Condition:   Adrenocortical Carcinoma Intervention:   Drug: Camrelizumab Sponsor:   West China Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials